Emyria Commences Empax PTSD Care Program at Perth Clinic and Launches Interstate Expansion
Emyria’s (ASX: EMD) has begun delivering its Empax therapy for post-traumatic stress disorder (PTSD) at a Perth clinic under Australia’s first private health insurance program for psychedelic-assisted treatment.
Medibank Private (ASX: MPL) is funding the program under an initial two-year agreement secured in June and will make it available to eligible health fund members.
The deal validates Emyria’s clinical protocols and provides the company with a scalable reimbursement pathway, significantly reducing the financial barrier for patients and demonstrating the commercial viability of the Empax platform while establishing a precedent for future agreements with other major insurers.
Growing Demand
Availability at the Perth clinic is nearing capacity for the remainder of this year and Emyria is reportedly engaging additional psychiatrists, therapists, and support staff to meet the growing demand.
The company confirmed the investments would be capital-light and generate rapid return by directly expanding treatment capacity and revenue.
“The speed at which Perth Clinic has reached capacity provides a clear blueprint for future clinic deployments, strengthening confidence in our ability to roll out a scalable national network,” a statement read.
“The demand also reflects growing awareness and acceptance among clinicians and patients, reinforcing our first-mover advantage in an emerging sector with few competitors.”
Interstate Expansion
Based in Perth, Emyria is also advancing preparations for the opening of its first interstate Empax clinic to be located at Avive Clinic Brisbane.
“By partnering with leading hospitals such as Avive, we can leverage existing infrastructure and reduce capital requirements while accelerating time-to-market,” the company said.
“This interstate expansion underpins our vision to become Australia’s leading provider of evidence-backed, insurer-funded mental health care.”
Chronic Health Concern
Mental health is Australia’s leading chronic health concern with conditions such as PTSD affecting approximately 1 in 11 people (most commonly women, veterans and first responders).
The nation’s existing health systems are struggling to meet growing demand, creating an urgent and significant need for more effective, scalable and reimbursed treatment models.
Emyria has developed the clinically-validated, data-driven Empax platform for repeatable expansion and is executing a national rollout to broaden access and deepen engagement with insurers, hospitals and regulators.